In a recent survey of pediatric dermatologists, cyclosporine (Neoral/ Novartis, SandIMMUNE/ Sandoz, others) was the most common choice of systemic agent to treat severe pediatric atopic dermatitis (AD), followed by methotrexate (Trexall, Teva, others).
Researchers from the University of North Carolina examined the gene expression and regulation in colon tissue from patients to better understand the cellular and molecular mechanisms that make up Crohn’s disease.
“While the concept of biofilms in atopic dermatitis is relatively new, antimicrobial and biofilm dispersing agents have been included in the treatment regimen for atopic dermatitis for decades," according to the study authors.
Multiple measurements of skin integrity and function were applied to distinguish between the effects of topical emollient products in a recent study. Two popular products in the UK were determined to transiently improve the skin barrier that is thought to be defective in atopic dermatitis (AD), and another product was confirmed to be damaging.